MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
278.20%
Quick Ratio
278.20%
Debt to Asset Ratio
15.52%
Unit: Dollar
Assets Breakdown
    • Light proton therapy system equi...
    • Cash
    • Operating lease right-of-use ass...
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Non-controlling interest
    • Others

Balance Sheets
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Cash
3,250,650 5,106,872 2,887,874 887,212
Prepaid insurance
56,031 26,682 29,490 14,597
Other prepaid expenses
101,069 44,825 61,839 87,943
Digital assets
NaN NaN 2,454,473 NaN
Total current assets
3,407,750 5,178,379 5,433,676 989,752
Light proton therapy system equipment
6,607,419 6,582,560 NaN NaN
Deferred offering costs
NaN NaN NaN 198,826
Operating lease right-of-use assets
850,129 972,682 NaN NaN
Total assets
10,865,298 12,733,621 5,433,676 1,188,578
Related parties accounts payable and accrued expenses
391,081 436,482 235,900 92,149
Research and development contract liabilities
238,435 232,138 235,155 256,147
Operating lease obligations, current
595,418 595,418 NaN NaN
Accrued offering costs
NaN NaN NaN 188,826
Series b convertible preferred stock 8 cumulative dividend payable
NaN 69,073 50,367 NaN
Total current liabilities
1,224,934 1,333,111 521,422 537,122
Operating lease obligations, long-term
461,772 438,959 NaN NaN
Total liabilities
1,686,706 1,772,070 NaN NaN
Preferred stock, value
NaN 1,731,569 2,553,359 NaN
Common stock, 0.0001 par value 100,000,000 shares authorized 11,632,944 and 8,790,102 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively
1,162 879 570 276
Additional paid-in capital
67,944,759 66,008,824 57,891,644 54,204,101
Accumulated deficit
-60,000,889 -58,077,213 -55,533,319 -53,552,921
Total lixte biotechnology stockholders equity
7,945,032 9,664,059 4,912,254 651,456
Non-controlling interest
1,233,560 1,297,492 NaN NaN
Total stockholders equity
9,178,592 10,961,551 NaN NaN
Total liabilities and stockholders equity
10,865,298 12,733,621 5,433,676 1,188,578
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash$3,250,650 Other prepaidexpenses$101,069 Prepaid insurance$56,031 Light proton therapysystem equipment$6,607,419 Total current assets$3,407,750 Operating leaseright-of-use assets$850,129 Total assets$10,865,298 Total liabilities andstockholders equity$10,865,298 Total stockholdersequity$9,178,592 Total liabilities$1,686,706 Total lixtebiotechnology stockholders...$7,945,032 Non-controlling interest$1,233,560 Total currentliabilities$1,224,934 Operating leaseobligations, long-term$461,772 Accumulated deficit-$60,000,889 Additional paid-in capital$67,944,759 Operating leaseobligations, current$595,418 Related partiesaccounts payable and...$391,081 Research and developmentcontract liabilities$238,435 Common stock, 0.0001par value...$1,162

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)